Clinical Trials

Regeneron Pharmaceuticals, Inc. announced promising results from the Phase 3 QUASAR trial investigating EYLEA HD® (aflibercept) Injection 8 mg for treating macular edema in patients with retinal vein occlusion (RVO). The results were presented during the Angiogenesis 2025 annual...

Pfizer has announced groundbreaking results from the Phase 3 BREAKWATER trial, showcasing the effectiveness of its BRAFTOVI® (encorafenib) combination regimen in the treatment of metastatic colorectal cancer (mCRC) with the BRAF V600E mutation. The trial highlights significant improvements in...

EVerZom, a biopharmaceutical company developing  exosome based biodrugs, announces that it has reached a key milestone in its development with the production of a first exosome GMP batch in a 10L bioreactor with unprecedented yields. Regulatory validation of the technology was carried out in GMP clean rooms of...

The most recent trial of a new antibody drug that goes on to deliver potent chemotherapy that too directly to the cancer cells for patients with advanced or recurrent endometrial cancer has gone a notch up to be studied...

Duality Biotherapeutics from China has gone ahead and filed paperwork as far as a Hong Kong IPO is concerned, thereby looking out for an undisclosed sum so as to power a broad pipeline when it comes to antibody conjugates...

PhotonPharma, a cutting-edge biopharmaceutical company based in Fort Collins, Colorado, is pleased to announce the successful closing of a $2.5 million seed financing round. This vital funding will support the Phase I clinical trial of Innocell™, an innovative therapy...

The resultant biotech, which the businesses announced on Thursday, would have a pipeline that may produce 10 clinical readouts over the next 18 months, with a combined cash of $850 million. According to a statement made on Thursday, the AI-enabled...